Kala Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.

ARLINGTON, Mass., March 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 29, 2022. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Altamira Therapeutics Ltd

Humanigen

Arcadia Biosciences

Nasdaq Penny Stocks List For March The post 4 Nasdaq Penny Stocks To Buy For Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Nasdaq Penny Stocks To Buy For Under $5

AquaBounty Technologies

Exela Technologies

4 Hot Penny Stocks To Buy According To Analysts. The post 4 Penny Stocks With Huge Potential According To Analyst Forecasts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks With Huge Potential According To Analyst Forecasts

UnitedHealthcare has added Kala Pharmaceuticals Inc's (NASDAQ: KALA) Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies effective March 2022.  Eysuvis now has coverage for approximately 118 million lives or 70% of.

This Microcap Pharma Stock Almost Doubled Today - Read Why

Kala Pharma (KALA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Kala Pharmaceuticals (KALA) Report Negative Q4 Earnings? What You Should Know

Harbor Custom Development, Inc.

Katapult Holdings

Leap Therapeutics

Vertex Energy

Looking for short squeeze penny stocks? Give these 5 a look.

Best Penny Stocks To Buy Now For A Short Squeeze? 5 To Watch

Kala Pharmaceuticals Inc (NASDAQ: KALA) has acquired Combangio Inc, a private company developing regenerative biotherapies for severe ocular surface diseases.  Combangio is developing CMB-012, a secretome therapy, to address the complex wound healing process in persistent corneal epithelial defect (PCED) and other severe ocular diseases driven by impaired corneal healing.

Kala Pharma Acquires Ocular Surface Disease-Focused Company

Kala Pharma (KALA) delivered earnings and revenue surprises of 4.44% and -40.77%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Kala Pharmaceuticals (KALA) Reports Q3 Loss, Misses Revenue Estimates

Kala Pharmaceuticals' (KALA) CEO Mark Iwicki on Q3 2021 Results - Earnings Call Transcript

Progenity

SmileDirectClub

Senseonics Holdings

Solid Biosciences

Short squeeze penny stocks to watch right now. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Now

-- Achieved $3.1 Million in Net Revenue in 3Q 2021 -- -- EYSUVIS® Prescriptions Increased by 19% Compared to 2Q 2021 -- Expanding Clinical-Stage Pipeline Through Acquisition of Combangio -- -- Conference Call and Webcast at 10:30 a.m. ET -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-- KPI-012 is a novel secretome with a multifactorial mechanism of action for development in PCED and other orphan ocular surface diseases driven by impaired corneal healing -- -- KPI-012 demonstrated positive safety and efficacy results in PCED Phase 1b clinical trial -- -- Kala expects to initiate Phase 2/3 trial in 3Q 2022 -- --Mark S. Blumenkranz, M.D., Professor Emeritus in the Department of Ophthalmology at Stanford University, appointed to Kala's Board of Directors -- -- Management to host conference call at 10:30 a.m. ET today -- WATERTOWN, Mass., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it has acquired Combangio, Inc., a private, clinical-stage company developing regenerative biotherapies for severe ocular surface diseases. Combangio is developing CMB-012, a novel investigational secretome therapy, now known as KPI-012, to address the complex wound healing process in persistent corneal epithelial defect (PCED) and other severe ocular diseases driven by impaired corneal healing.

Kala Pharmaceuticals Acquires Combangio, Expanding its Pipeline with a Clinical-Stage Novel Biologic for the Treatment of Persistent Corneal Epithelial Defect (PCED) and other Rare Ocular Surface Diseases

WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in November 2021:

Kala Pharmaceuticals to Participate in Upcoming Investor Conferences in November 2021

WATERTOWN, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report third quarter 2021 financial results on Monday, November 15, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:30 a.m. ET.

Kala Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call

Clear Channel Outdoor Holdings

Digital Brands Group Inc

Liquidia Technologies Inc

4 penny stocks to watch this week. The post 4 Top Penny Stocks To Watch After FOMC Meeting In November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Watch After FOMC Meeting In November

Vinco Ventures

Bitfarms Ltd

Clovis Oncology

Meta Materials

Romeo Power

Electrameccanica

Voyager Therapeutics

Wish

If you're like most traders right now, you're looking for an edge.… The post Best Penny Stocks To Buy For A Short Squeeze?

Best Penny Stocks To Buy For A Short Squeeze? 10 To Watch Today

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that management will participate in the following virtual healthcare investor conferences in September 2021:

Kala Pharmaceuticals to Present at Upcoming Investor Conferences in September 2021

The SPRT stock breakout has shed light on other short-squeeze penny stocks The post 4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Short Squeeze Penny Stocks To Watch After SPRT Stock's 1,309% Run

Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q2 2021 Results - Earnings Call Transcript

-- EYSUVIS Prescriptions Increased by 93% Compared to First Quarter of 2021 -- -- Further Expanded Commercial Coverage for EYSUVIS to More Than 96 Million Lives -- -- Achieved $3.1 Million in Net Revenue in Second Quarter of 2021 -- -- Conference Call and Webcast at 8:00 a.m. ET -- WATERTOWN, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Kala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Earnings Preview: Kala Pharmaceuticals (KALA) Q2 Earnings Expected to Decline

WATERTOWN, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report second quarter 2021 financial results on Thursday, August 5, 2021. Management will host a conference call and live audio webcast to discuss these results and provide a business update at 8:00 a.m. ET.

Kala Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that OptumRx, one of the largest pharmacy benefit managers (PBM) in the United States, has added EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% as a covered brand on its commercial formularies, effective May 21, 2021. “We are pleased to announce the addit

Kala Pharmaceuticals Announces EYSUVIS® Now Covered by OptumRx

WATERTOWN, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present at the Jefferies 2021 Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, June 3, 2021 at 10:00 am ET. To access the webcast and subsequent archived recording of the presentation, please visit “Even

Kala Pharmaceuticals to Present at Jefferies 2021 Virtual Healthcare Conference

ALEXANDRIA, Va.--(BUSINESS WIRE)--Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals

Oxford Finance Provides $125 Million Credit Facility to Kala Pharmaceuticals

News for Kala Pharmaceuticals Stock (KALA)